• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

“Chillin’ Out” and Finding Our Cancer Community

by MM360 Staff | Apr 20, 2025 | Uncategorized

Source: CureToday articles After nearly 30 years with cancer — community, research and education have helped us find hope, strength and purpose in the face of chronic blood cancers. Read More

Bavencio Maintains Bladder Cancer Benefit in Patients with Diabetes

by MM360 Staff | Apr 20, 2025 | Uncategorized

Source: CureToday articles Bavencio improved survival in patients with bladder cancer, irrespective of diabetes status, according to an analysis of the JAVELIN Bladder 100 trial. Read More

Optimal Jakafi Dosing Associated With Improved Outcomes in Myelofibrosis

by MM360 Staff | Apr 19, 2025 | Uncategorized

Source: CureToday articles Optimal dosing of Jakafi was associated with improved efficacy and manageable safety in patients with myelofibrosis, according to the ROMEI clinical trial. Read More

Illuminating Compassion in Cancer Care

by MM360 Staff | Apr 19, 2025 | Uncategorized

Source: CureToday articles The journey that led to the creation of the Extraordinary Healer Award for Oncology Nursing began with a simple, yet profound, observation. Read More

Renowned Breast Cancer Physician-Scientist Dr. Hope S. Rugo to Lead City of Hope’s Women’s Cancers Program

by MM360 Staff | Apr 18, 2025 | Uncategorized

Source: CureToday articles Dr. Rugo has led key breast cancer therapy trials and exudes a passion for serving patients. Read More

Reassessing Immunotherapy Use in Advanced Renal Cell Carcinoma

by MM360 Staff | Apr 18, 2025 | Uncategorized

Source: CureToday articles There is currently no strong evidence that additional immune therapy benefits patients with renal cell carcinoma who were treated in the advanced setting. Read More
« Older Entries
Next Entries »

Recent Content

  • (no title)
  • New center promotes advocacy for gynecological cancer patients
  • FDA clears Thermo Fisher EXTENT system for myeloma diagnosis
  • Microbiome modulation uncouples efficacy and toxicity induced by immune checkpoint blockade in mouse multiple myeloma
  • TSCM-predominant allogeneic anti-BCMA CAR-T therapy for relapsed/refractory multiple myeloma: preclinical characterization and interim results from a phase 1 trial
  • (no title)
  • (no title)
  • New ‘powerful’ lab test will help researchers explore blood cancer
  • Assessing the correlation between patient and family reported outcome measures and multiple myeloma clinical parameters
  • Defining the proteome of bone marrow plasma in multiple myeloma and monoclonal gammopathy of undetermined significance
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT